| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 01/15/2004 | US20040009214 An antianxiety agent such as buspirone; a dermal penetration enhancer of given formula such as octyl salicylate; and a volatile liquid such as ethanol |
| 01/15/2004 | US20040009213 Water-based delivery systems |
| 01/15/2004 | US20040009212 .2-.5% of a mucoadhesive polymer of carboxylvinylpolyester (i.e. carbopol or carbomer) and celluloses, 15%-40% of a thermoresponsive polymer having two critical points and a balance of water |
| 01/15/2004 | US20040009180 Transdermal botulinum toxin compositions |
| 01/15/2004 | US20040009168 Multidose antibody formulation |
| 01/15/2004 | US20040009167 Chimeric molecules that contain at least one pathogen-detection domain and at least one effector domain; use in preventing or treating a pathogen infection in a cell or organism |
| 01/15/2004 | US20040009166 Single chain antigen-binding polypeptides for polymer conjugation |
| 01/15/2004 | US20040009155 Method for sustaining direct cell delivery |
| 01/15/2004 | US20040009126 Inhalation system for prevention and treatment of intracellular infections |
| 01/15/2004 | US20040009122 A formulation V-L-R where v is a vector moiety having affinity for an angiogenesis-related endothelial cell receptor, L is a linker or a bond and R is a detectable moiety (v is nonpeptidic or peptide and R is a macromolecule) |
| 01/15/2004 | DE10228049A1 Flüssige Zubereitung enthaltend Oligopeptide The liquid formulation containing oligopeptides |
| 01/15/2004 | DE10227935A1 Antibiotische Beschichtung von porösen Körpern und Verfahren zu ihrer Herstellung sowie Verwendung The antibiotic coating of porous bodies and processes for their preparation and use |
| 01/15/2004 | DE10227914A1 Pharmazeutische Zubereitung mit retardierender Wirkstofffreisetzung, Verfahren zu ihrer Herstellung und Verwendung Pharmaceutical formulation having retarded active substance release, methods for their preparation and use |
| 01/15/2004 | DE10227232A1 Saure Insulinzubereitungen mit verbesserter Stabilität Acidic insulin preparations with improved stability |
| 01/15/2004 | CA2492037A1 Novel drug compositions based on novel anticholinergics and inhibitors of egfr-kinase |
| 01/15/2004 | CA2492033A1 Pharmaceutical compositions of anticholinergics and p38 kinase inhibitors in the treatment of respiratory diseases |
| 01/15/2004 | CA2492026A1 New pharmaceutical compositions based on new anticholinergics and pde-iv inhibitors |
| 01/15/2004 | CA2491724A1 Ciclesonide-containing sterile aqueous suspension |
| 01/15/2004 | CA2491710A1 Epa and dha enriched omega-3 supplement for the treatment of dry eye, meibomianitis and xerostomia |
| 01/15/2004 | CA2491685A1 Liquid formulations with high concentration of human growth hormone (hgh) comprising 1,2-prolpylene glycol |
| 01/15/2004 | CA2491682A1 Liquid formulations with a high concentration of human growth hormone (hgh) comprising glycine |
| 01/15/2004 | CA2491513A1 Compositions and methods for ligament growth and repair |
| 01/15/2004 | CA2491484A1 Scanning suspension comprising a particle with a diameter of at least 1 micrometer |
| 01/15/2004 | CA2491478A1 Liquid formulations with high concentration of human growth hormone (hgh) comprising phenol |
| 01/15/2004 | CA2491451A1 Novel pharmaceutical compositions comprising novel anticholinergic agents and nk1-receptor antagonists |
| 01/15/2004 | CA2491355A1 Controlled release compositions comprising coated pellets having non-uniform coating thicknesses |
| 01/15/2004 | CA2491128A1 Treatment for eye disorder |
| 01/15/2004 | CA2491054A1 Compositions of hyaluronic acid and methods of use |
| 01/15/2004 | CA2491017A1 Antibodies to non-shed muc1 and muc16, and uses thereof |
| 01/15/2004 | CA2490952A1 Vitamin-containing system for stabilising the immune response of animals |
| 01/15/2004 | CA2490142A1 Liquid dosage forms of proton pump inhibitors |
| 01/15/2004 | CA2489919A1 Liposomal vaccine |
| 01/15/2004 | CA2489563A1 Compositions and methods for amelioration of human female sexual dysfunction |
| 01/15/2004 | CA2489071A1 Solid dispersions comprising two different polymer matrixes |
| 01/14/2004 | EP1380645A2 Production in bacteria ad yeast of hemoglobin and analogues thereof |
| 01/14/2004 | EP1380639A1 Method for producing a water-alcohol solution and products based thereon |
| 01/14/2004 | EP1380595A1 Branched cyclic tetrassacharide, process for producing the same, and use |
| 01/14/2004 | EP1380308A1 Quickly disintegrable compression-molded materials and process for producing the same |
| 01/14/2004 | EP1380297A1 8-chloro-6, 11-dihydro-11-(4-piperidylidene)-5H-benzo[5,6]cyclo-hepta[1,2-b]pyridine oral compositions |
| 01/14/2004 | EP1379672A2 Chimeric molecules containing a module able to target specific cells and a module regulating the apoptogenic function of the permeability transition pore complex (ptpc) |
| 01/14/2004 | EP1379575A1 Composition for soluble films with a new hydrolyzed polysaccharide |
| 01/14/2004 | EP1379542A2 Treatment of tumours |
| 01/14/2004 | EP1379513A1 Prodrugs of cox-2 inhibitors |
| 01/14/2004 | EP1379499A1 New diaminedithiol derivatives and radiorhenium or radiotechnetium complex thereof; a liver cancer-treating composition comprising the radiorhenium complex and lipiodol; and a kit for preparation of the liver cancer-treating composition |
| 01/14/2004 | EP1379280A2 Immunogenic complex |
| 01/14/2004 | EP1379279A1 Orally deliverable pharmaceutical composition comprising a drug of low water solubility (cox-2 inhibitor), a solvent, a fatty acid and an organic amine |
| 01/14/2004 | EP1379277A2 Polyclonal populations of bispecific molecules and methods of production and uses thereof |
| 01/14/2004 | EP1379266A2 Modified annexin proteins and methods for preventing thrombosis |
| 01/14/2004 | EP1379257A2 Prodrugs of anticancer agents employing substituted aromatic acids |
| 01/14/2004 | EP1379254A1 Use of bile acid or bile salt fatty acid conjugates |
| 01/14/2004 | EP1379242A1 Method for treatment of cancer and compositions for use therein |
| 01/14/2004 | EP1379235A2 Compositions and methods for enhancing paracellular permeability across epithelial and endothelial barriers |
| 01/14/2004 | EP1379233A1 Use of a substantially cell membrane impermeable compound for treating arthritis |
| 01/14/2004 | EP1379230A1 Method of using pyruvate and/or its derivatives for the treatment of cytokine-mediated inflammatory conditions |
| 01/14/2004 | EP1379227A1 Microemulsions as precursors to solid nanoparticles |
| 01/14/2004 | EP1379225A2 Novel medicament compositions based on anticholinergic agents and endothelin antagonists |
| 01/14/2004 | EP1379224A1 Guanylate cyclase receptor agonists for the treatment of tissue inflammation and carcinogenesis |
| 01/14/2004 | EP1379223A1 Dental formulation |
| 01/14/2004 | EP1379221A2 Pharmaceutical product with reticulated crystalline microstructure |
| 01/14/2004 | EP1379220A2 Inhalation capsules |
| 01/14/2004 | EP1379219A2 Large, porous particles produced controlling humidity during a spray draying process |
| 01/14/2004 | EP1379207A1 Composition for freshening nostrils and sinus cavities |
| 01/14/2004 | EP1379203A1 Condom with an erectogenic composition |
| 01/14/2004 | EP1379197A1 Delivery of drugs from sustained release devices implanted in myocardial tissue or in the pericardial space |
| 01/14/2004 | EP1379138A1 Liquid formulations for dermal application in treatment of parasitic insects in animals |
| 01/14/2004 | EP1379135A1 Formulations comprising entrapped active ingredients and uses thereof |
| 01/14/2004 | EP1124534B1 Expandable gastroretentive therapeutical system with prolonged stomach retention time |
| 01/14/2004 | EP1082117B1 A stabilized antihistamine syrup containing aminopolycarboxylic acid as stabilizer |
| 01/14/2004 | EP0900088B1 Inclusion complexes of aryl-heterocyclic salts |
| 01/14/2004 | EP0816381B1 Polyethylene glycol modified hepatocyte growth factor (hgf) |
| 01/14/2004 | EP0758227B1 Modulated release from biocompatible polymers |
| 01/14/2004 | EP0705097B2 Incorporating poly-n-vinyl amide in a transdermal system |
| 01/14/2004 | CN1468253A 17.beta.-carbothioate 17.alpha.-arylcarbonyloxyloxy androstane derivative as anti-inflammatory agents |
| 01/14/2004 | CN1468252A 6.alpha., 9.alpha.-difluoro-17.alpha.-[(2-furanylcarboxyl) oxy]-11.beta.-hydroxy-16.alpha.-methyl-3-oxo-androst-1,4,-diene-17-carbothioic acid s-fluoromethyl ester as an anti-inflammatory agent |
| 01/14/2004 | CN1468209A Stable salts of o-acetylsalicyclic with basic amino acids |
| 01/14/2004 | CN1468144A Colloidal suspension of submicronic particles for carrying active principles and their mode of preparation |
| 01/14/2004 | CN1468123A Method and composition for altering a b cell mediated pathology |
| 01/14/2004 | CN1468120A Electro-powder |
| 01/14/2004 | CN1468105A Use of probiotic lactic acid bacteria for balancing the skin's immune system |
| 01/14/2004 | CN1468102A Modified prodrug forms of ap/amp |
| 01/14/2004 | CN1468097A Compositions comprising modafinil compounds |
| 01/14/2004 | CN1468096A Pharmaceutical solutions of modafinil compounds |
| 01/14/2004 | CN1468095A Colloidal suspension of submicronic particles for carrying hydrophilic active principles (insulin) and method for preparing same |
| 01/14/2004 | CN1468093A Biodegradable microparticles for controlled release administration, with purified amylopectin-based starch of reduced molecular weight |
| 01/14/2004 | CN1468091A Vaccine composition and stabilisation method |
| 01/14/2004 | CN1468089A Microparticles for delivery of the heterologous nucleic acids |
| 01/14/2004 | CN1467248A Biodegradable biopolymers, method for their preparation and functional materials constituted by these biopolymers |
| 01/14/2004 | CN1466952A External preparations for treating dermatitis |
| 01/14/2004 | CN1466939A Cosmetic and/or dermatological use of a composition containing at least one oxidation-sensitive hydrophilic active stabilised by at least one polymer or copolymer of maleic anhydride |
| 01/14/2004 | CN1134486C Antiviral dendrimers |
| 01/14/2004 | CN1134479C Process for producing polymer |
| 01/14/2004 | CN1134258C Polymer coated tablet comprising amoxycillin and clavulanate |
| 01/14/2004 | CN1134254C Transdermal therapeutic system (TTS) contg. oxybutynin |
| 01/14/2004 | CN1134253C Oral slow-releasing opioid formulations and method for preparing the same |
| 01/13/2004 | USRE38385 Proteins, peptides, nucleosides, nucleotides; carrier carbohydrates and and sugars which are water soluble or water swellable and in a glassy amorphous state; storage stability |
| 01/13/2004 | US6677492 Sevoflurane |
| 01/13/2004 | US6677445 Chimeric antisense oligonucleotides and cell transfecting formulations thereof |
| 01/13/2004 | US6677440 Isolating by anion- and/or cation-exchange chromatography at ph value below isoelectric point of protein to be isolated or combination of ion exchange chromatography with affinity chromatography and/or fractional precipitation at specified ph |
| 01/13/2004 | US6677438 Method for attaching polyethylene glycol to macromolecules |
| 01/13/2004 | US6677431 Design, preparation, and properties of antibacterial β-peptides |